VTVT

vTv Therapeutics Inc.

14.52 USD

Last updated Nov 30, 08:33 UTC

Yesterday HIGH

$16.2

Yesterday LOW

$10.32

52w HIGH

$42

52w LOW

$8.46

EPS

-0.08

PE

-181.50

Next Earnings

Mar 4, 2024

Overview News Government Trades

vTv Therapeutics Inc. stock is down -12.95% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 22.22% of the previous 8 November’s closed higher than October.

vTv Therapeutics focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

High Point, United States Of America

Website

vtvtherapeutics.com

Benzinga Newsdesk

Thu Apr 20, 2023

Cantex And Michigan Medicine Announce Initiation Of A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study To Determine The Safety And Efficacy Of Azeliragon In The Treatment Of Patients Hospitalized For COVID-19

Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, and Michigan Medicine, a part of the
richadhand@benzinga.com

Tue Mar 7, 2023

HC Wainwright & Co. Reiterates Buy on vTv Therapeutics, Maintains $6 Price Target

HC Wainwright & Co. analyst Vernon Bernardino reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $6 price target.
Michael Horton

Mon Mar 6, 2023

vTv Therapeutics Q4 EPS $(0.06), Inline, Sales $9.00K, Same YoY

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 45.45 percent increase over losses of $(0.11) per share from the same period last year.
Benzinga Insights

Mon Mar 6, 2023

12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Newsdesk

Mon Mar 6, 2023

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, and Baptist Health Miami Cancer
Bill Haddad

Mon Feb 27, 2023

Cantex Receives FDA 'Study May Proceed' Letter For Phase 2 Clinical Trial Of Azeliragon For Treatment Of Unmethylated Glioblastoma

Azeliragon, previously known as TTP488, is an orally active, small molecule, antagonist of the receptor for advanced glycation end products (RAGE) licensed by Cantex from vTv Therapeutics Inc. (NASDAQ:VTVT). vTv
Benzinga Insights

Tue Jan 10, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Newsdesk

Mon Jan 9, 2023

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Glioblastoma

Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently
Benzinga Newsdesk

Tue Dec 13, 2022

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch As Chief Financial Officer Effective Immediately

vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Steven Tuch as
Michael Horton

Thu Nov 10, 2022

vTv Therapeutics Q3 EPS $(0.05) Down From $(0.02) YoY

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.05) per share. This is a 150 percent decrease over losses of $(0.02) per share from the same period last year.